Efficacy and safety of two artificial saliva-based polymers containing 0.1% pilocarpine for treatment of xerostomia: A randomized clinical pilot trial.
Journal
Journal of clinical and experimental dentistry
ISSN: 1989-5488
Titre abrégé: J Clin Exp Dent
Pays: Spain
ID NLM: 101603132
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
19
03
2021
accepted:
24
05
2021
entrez:
20
10
2021
pubmed:
21
10
2021
medline:
21
10
2021
Statut:
epublish
Résumé
Topical agents are the mainstay in the treatment of xerostomia, a common complaint most frequently associated with salivary dysfunction. This study aimed to compared the efficacy and safety for xerostomia treatment of 2 artificial saliva preparations containing 0.1% pilocarpine, and, either sodium carboxymethylcellulose (SCMC), or, sodium polyacrylate (SPA). Thirty-one xerostomia patients were randomly allocated into either a SCMC-treated group (15 patients), or, a SPA-treated group (16 patients). The formulations were taken 0.5 ml, 4 times daily for 6 weeks and double-blinded assessed before and after treatments using Xerostomia Inventory (XI) and Clinical Oral Dryness Score (CODs). Unstimulated and stimulated whole salivary flow rates were measured. After treatment, the SCMC-treated group had significantly lower CODs and higher unstimulated and stimulated whole salivary flow rates ( This randomized controlled pilot trial demonstrated superior efficacy of SCMC-formula over a SPA-formula after 6 weeks of xerostomia treatment. These formulations with topical pilocarpine proved safe in clinical use with minimal reported AE.
Sections du résumé
BACKGROUND
BACKGROUND
Topical agents are the mainstay in the treatment of xerostomia, a common complaint most frequently associated with salivary dysfunction. This study aimed to compared the efficacy and safety for xerostomia treatment of 2 artificial saliva preparations containing 0.1% pilocarpine, and, either sodium carboxymethylcellulose (SCMC), or, sodium polyacrylate (SPA).
MATERIAL AND METHODS
METHODS
Thirty-one xerostomia patients were randomly allocated into either a SCMC-treated group (15 patients), or, a SPA-treated group (16 patients). The formulations were taken 0.5 ml, 4 times daily for 6 weeks and double-blinded assessed before and after treatments using Xerostomia Inventory (XI) and Clinical Oral Dryness Score (CODs). Unstimulated and stimulated whole salivary flow rates were measured.
RESULTS
RESULTS
After treatment, the SCMC-treated group had significantly lower CODs and higher unstimulated and stimulated whole salivary flow rates (
CONCLUSIONS
CONCLUSIONS
This randomized controlled pilot trial demonstrated superior efficacy of SCMC-formula over a SPA-formula after 6 weeks of xerostomia treatment. These formulations with topical pilocarpine proved safe in clinical use with minimal reported AE.
Identifiants
pubmed: 34667494
doi: 10.4317/jced.58415
pii: 58415
pmc: PMC8501859
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e994-e1000Informations de copyright
Copyright: © 2021 Medicina Oral S.L.
Déclaration de conflit d'intérêts
Conflicts of interest The authors declare that they have no conflicts of interest.
Références
BMC Cancer. 2018 Mar 2;18(1):245
pubmed: 29499657
Int J Mol Sci. 2019 Jun 29;20(13):
pubmed: 31261876
Community Dent Health. 1999 Mar;16(1):12-7
pubmed: 10697349
J Physiol Pharmacol. 2017 Dec;68(6):807-813
pubmed: 29550792
Crit Rev Ther Drug Carrier Syst. 1988;5(1):21-67
pubmed: 3293807
Braz J Med Biol Res. 2002 Jan;35(1):105-10
pubmed: 11743622
Arch Oral Biol. 2015 Feb;60(2):242-55
pubmed: 25463902
Int J Oral Maxillofac Surg. 2008 Nov;37(11):1027-31
pubmed: 18640823
Oral Oncol. 1999 Mar;35(2):132-7
pubmed: 10435146
J Oral Rehabil. 2014 Mar;41(3):226-35
pubmed: 24527846
J Clin Oncol. 1993 Jun;11(6):1124-31
pubmed: 8501499
Oral Dis. 2020 Apr 5;:
pubmed: 32248594
Br J Dermatol. 2018 Nov;179(5):1056-1061
pubmed: 29432648
Br Dent J. 1991 Apr 6;170(7):251
pubmed: 2025451
Clin Oral Investig. 2015 Sep;19(7):1563-80
pubmed: 25994331
Clin Dermatol. 2017 Sep - Oct;35(5):468-476
pubmed: 28916028
Spec Care Dentist. 2015 Jul-Aug;35(4):164-9
pubmed: 25639487
Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Nov;114(5):597-603
pubmed: 22959491
J Med Assoc Thai. 2008 Sep;91(9):1410-5
pubmed: 18843872
Strahlenther Onkol. 2005 Apr;181(4):231-6
pubmed: 15827692
Spec Care Dentist. 1998 May-Jun;18(3):113-8
pubmed: 9680921
Aust Dent J. 2010 Sep;55(3):238-44; quiz 353
pubmed: 20887509
J Clin Exp Dent. 2021 Feb 1;13(2):e104-e111
pubmed: 33574994
Int J Biol Macromol. 2019 Jul 15;133:21-29
pubmed: 30986470
J Oral Pathol. 1983 Oct;12(5):336-41
pubmed: 6415255
J Pharm Pharm Sci. 1999 May-Aug;2(2):53-61
pubmed: 10952770
Mol Pharmacol. 2017 Nov;92(5):601-612
pubmed: 28893976
Aust Dent J. 2006 Dec;51(4):333-7
pubmed: 17256309